Extended newborn screening using DNA methylation testing for fragile X syndrome in 17,107 infants

There is interest in newborn screening for fragile X syndrome (FXS) because of the potential benefits of early diagnosis and treatment and the prevention of future affected births through informed reproductive choices. This study examined the feasibility of newborn screening for FXS on a population scale.